246 related articles for article (PubMed ID: 28640161)
21. Dehydroepiandrosterone intra vaginal administration for the management of postmenopausal vulvovaginal atrophy.
Archer DF
J Steroid Biochem Mol Biol; 2015 Jan; 145():139-43. PubMed ID: 25201455
[TBL] [Abstract][Full Text] [Related]
22. Ospemifene, a non-oestrogen selective oestrogen receptor modulator for the treatment of vaginal dryness associated with postmenopausal vulvar and vaginal atrophy: a randomised, placebo-controlled, phase III trial.
Portman D; Palacios S; Nappi RE; Mueck AO
Maturitas; 2014 Jun; 78(2):91-8. PubMed ID: 24679891
[TBL] [Abstract][Full Text] [Related]
23. The therapeutic effect of dehydroepiandrosterone (DHEA) on vulvovaginal atrophy.
Wang J; Wang L
Pharmacol Res; 2021 Apr; 166():105509. PubMed ID: 33610719
[TBL] [Abstract][Full Text] [Related]
24. A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women.
Kagan R; Williams RS; Pan K; Mirkin S; Pickar JH
Menopause; 2010 Mar; 17(2):281-9. PubMed ID: 19779382
[TBL] [Abstract][Full Text] [Related]
25. Visual improvements in vaginal mucosa correlate with symptoms of VVA: data from a double-blind, placebo-controlled trial.
Simon JA; Archer DF; Kagan R; Bernick B; Graham S; Constantine GD; Mirkin S
Menopause; 2017 Sep; 24(9):1003-1010. PubMed ID: 28419068
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of ospemifene in postmenopausal women with moderate-to-severe vaginal dryness: a phase 3, randomized, double-blind, placebo-controlled, multicenter trial.
Archer DF; Goldstein SR; Simon JA; Waldbaum AS; Sussman SA; Altomare C; Zhu J; Yoshida Y; Schaffer S; Soulban G
Menopause; 2019 Jan; 26(6):611-621. PubMed ID: 30694917
[TBL] [Abstract][Full Text] [Related]
27. Assessment of ospemifene or lubricants on clinical signs of VVA.
Constantine G; Graham S; Koltun WD; Kingsberg SA
J Sex Med; 2014 Apr; 11(4):1033-1041. PubMed ID: 24443923
[TBL] [Abstract][Full Text] [Related]
28. Serum steroid concentrations remain within normal postmenopausal values in women receiving daily 6.5mg intravaginal prasterone for 12 weeks.
Martel C; Labrie F; Archer DF; Ke Y; Gonthier R; Simard JN; Lavoie L; Vaillancourt M; Montesino M; Balser J; Moyneur É;
J Steroid Biochem Mol Biol; 2016 May; 159():142-53. PubMed ID: 26972555
[TBL] [Abstract][Full Text] [Related]
29. TX-004HR Improves Sexual Function as Measured by the Female Sexual Function Index in Postmenopausal Women With Vulvar and Vaginal Atrophy: The REJOICE Trial.
Kingsberg SA; Derogatis L; Simon JA; Constantine GD; Graham S; Bernick B; Gasper G; Mirkin S
J Sex Med; 2016 Dec; 13(12):1930-1937. PubMed ID: 27692842
[TBL] [Abstract][Full Text] [Related]
30. Early onset of action with a 17β-estradiol, softgel, vaginal insert for treating vulvar and vaginal atrophy and moderate to severe dyspareunia.
Constantine G; Millheiser LS; Kaunitz AM; Parish SJ; Graham S; Bernick B; Mirkin S
Menopause; 2019 Nov; 26(11):1259-1264. PubMed ID: 31688572
[TBL] [Abstract][Full Text] [Related]
31. High internal consistency and efficacy of intravaginal DHEA for vaginal atrophy.
Labrie F; Archer D; Bouchard C; Fortier M; Cusan L; Gomez JL; Girard G; Baron M; Ayotte N; Moreau M; Dubé R; Côté I; Labrie C; Lavoie L; Berger L; Martel C; Balser J
Gynecol Endocrinol; 2010 Jul; 26(7):524-32. PubMed ID: 20459349
[TBL] [Abstract][Full Text] [Related]
32. An overview of dehydroepiandrosterone (EM-760) as a treatment option for genitourinary syndrome of menopause.
Holton M; Thorne C; Goldstein AT
Expert Opin Pharmacother; 2020 Mar; 21(4):409-415. PubMed ID: 31928093
[No Abstract] [Full Text] [Related]
33. A randomized, multicenter, double-blind study to evaluate the safety and efficacy of estradiol vaginal cream 0.003% in postmenopausal women with dyspareunia as the most bothersome symptom.
Kroll R; Archer DF; Lin Y; Sniukiene V; Liu JH
Menopause; 2018 Feb; 25(2):133-138. PubMed ID: 28926514
[TBL] [Abstract][Full Text] [Related]
34. Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women.
Labrie F; Archer D; Bouchard C; Fortier M; Cusan L; Gomez JL; Girard G; Baron M; Ayotte N; Moreau M; Dubé R; Côté I; Labrie C; Lavoie L; Berger L; Gilbert L; Martel C; Balser J
Menopause; 2009; 16(5):923-31. PubMed ID: 19424093
[TBL] [Abstract][Full Text] [Related]
35. Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women's VIews of Treatment Options for Menopausal Vaginal ChangEs) survey.
Kingsberg SA; Wysocki S; Magnus L; Krychman ML
J Sex Med; 2013 Jul; 10(7):1790-9. PubMed ID: 23679050
[TBL] [Abstract][Full Text] [Related]
36. Effect of ospemifene on moderate or severe symptoms of vulvar and vaginal atrophy.
Bruyniks N; Nappi RE; Castelo-Branco C; de Villiers TJ; Simon J
Climacteric; 2016; 19(1):60-5. PubMed ID: 26669628
[TBL] [Abstract][Full Text] [Related]
37. Intravaginal Testosterone Improves Sexual Satisfaction and Vaginal Symptoms Associated With Aromatase Inhibitors.
Davis SR; Robinson PJ; Jane F; White S; White M; Bell RJ
J Clin Endocrinol Metab; 2018 Nov; 103(11):4146-4154. PubMed ID: 30239842
[TBL] [Abstract][Full Text] [Related]
38. Serum levels of sex steroids and metabolites following 12 weeks of intravaginal 0.50% DHEA administration.
Ke Y; Labrie F; Gonthier R; Simard JN; Bergeron D; Martel C; Vaillancourt M; Montesino M; Lavoie L; Archer DF; Balser J; Moyneur E;
J Steroid Biochem Mol Biol; 2015 Nov; 154():186-96. PubMed ID: 26291918
[TBL] [Abstract][Full Text] [Related]
39. ▼Prasterone for vulvar and vaginal atrophy.
Drug Ther Bull; 2019 Dec; 57(12):185-188. PubMed ID: 31578208
[No Abstract] [Full Text] [Related]
40. Ospemifene for the treatment of vulvar and vaginal atrophy: A meta-analysis of randomized trials. Part I: Evaluation of efficacy.
Di Donato V; Schiavi MC; Iacobelli V; D'oria O; Kontopantelis E; Simoncini T; Muzii L; Benedetti Panici P
Maturitas; 2019 Mar; 121():86-92. PubMed ID: 30509753
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
